12:00 AM
 | 
Jul 20, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NIC5-15: Phase IIa data

Data from double-blind, dose-escalation Phase IIa trial in 9 patients with mild to moderate AD showed that NIC5-15 was well tolerated. Cognitive performance remained stable for the...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >